Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET
Company Participants
Chad Fugere - Vice President, Investor Relations
Ian Mortimer - President and Chief Executive Officer
Chris Kenney - Chief Medical Officer
Sherry Aulin - Chief Financial Officer
Chris Von Seggern - Chief Commercial Officer
Conference Call Participants
Caroline Pocher - JPMorgan
Andrew Tsai - Jefferies
Brian Abrahams - RBC Capital Markets
Luke Herrmann - Baird
Jason Gerberry - Bank of America
Sarah Schram - William Blair
Paul Choi - Goldman Sachs
Danielle Brill - Raymond James
Marc Goodman - Leerink Partners
Joseph Thome - TD Cowen
Dylan Shindler - Wedbush Securities
Operator
Good afternoon, and thank you for standing by. At this time, I'd like to welcome everyone to Xenon Pharmaceuticals, Inc. Third Quarter 2024 Earnings Conference Call. [Operator Instructions]
I will now turn the conference over to Chad Fugere, Vice President of Investor Relations. Please go ahead, sir.
Chad Fugere
Good afternoon. Thank you for joining us on our call and webcast to discuss Xenon's third quarter 2024 financial and operating results. Joining me today are Ian Mortimer, Xenon's President and Chief Executive Officer; [technical difficulty]
Sherry Aulin
I'm just going to jump in for Chad. So Ian will begin with a summary of our recent progress across our business. Chris Kenney will provide an overview of our clinical stage programs and ongoing outreach to the medical community and I will close with a summary of our financial results and anticipated milestones. We will then open the call up for your questions.
Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding the timing of and potential results from clinical trials, the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market, regulatory success and commercial potential of our and our partners' product candidates, the efficacy of our clinical trial designs, our ability to successfully develop and achieve milestones in our clinical development programs, the timing and results of our interactions with regulators, our ability to successfully obtain regulatory approvals, anticipated timing of the top line data readout for our clinical trials of azetukalner and our expectation that we will have sufficient cash to fund operations into 2027.
Today's press release summarizing Xenon's third quarter 2024 financial results and the accompanying quarterly report on Form 10-Q will be made available under the Investors section of our website at xenon-pharma.com and filed with the SEC and on SEDAR+.